Do adherence rates and glaucomatous visual field progression correlate?

European Journal of Ophthalmology

Volumn 21, Issue 4, 2011, Pages 410-414

  Rossi, Gemma C M ^a   Pasinetti, Gian Maria ^b   Scudeller, Luigia ^a   Radaelli, Rosella ^c   Bianchi, Paolo Emilio ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b Istituto Beato Palazzolo   (Italy)

^c Eye Unit   (Italy)

Author keywords

Adherence; Glaucoma; Monitoring tools; Monotherapy; Travatan dosing aid ; Visual field progression

Indexed keywords

TIMOLOL PLUS TRAVOPROST; TRAVOPROST;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEVICE; DRUG MONITORING; HUMAN; INTRAOCULAR PRESSURE; OPEN ANGLE GLAUCOMA; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VISUAL FIELD; VISUAL SYSTEM FUNCTION;

AGED; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; DISEASE PROGRESSION; DRUG COMBINATIONS; FOLLOW-UP STUDIES; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIMOLOL; VISION DISORDERS; VISUAL ACUITY; VISUAL FIELDS;

EID: 79957871972     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/EJO.2010.6112     Document Type: Article

References (32)

1. Hattenhauer MG, Johnson DH, Ing HH, et al. The probability of blindness from open-angle glaucoma. Ophthalmology 1998; 105: 2099-104.
2. Grant WM, Burke JF. Why do some people go blind from glaucoma? Ophthalmology 1982; 89: 991-8.
3. Kwon YH, Kim CS, Zimmerman MB, Alward WL, Hayreh SS. Rate of visual field loss and long-term visual outcome in primary open-angle glaucoma. Am J Ophthalmol 2001; 132: 47-56.
4. Molteno ACB, Bosma NJ, Kittelson JM. Otago glaucoma surgery outcome study: long-term results of trabeculectomy 1976ñ1995. Ophthalmology 1999; 106: 1742-50.
5. Oliver JE, Hattenhauer MG, David DH, et al. Blindness and glaucoma: a comparison of patients progressing to blindness from glaucoma with patients maintaining vision. Am J Ophthalmol 2002; 133: 764-72.
6. Chen PP. Blindness in patients with treated open angle glaucoma. Ophthalmology 2003; 110: 726-33.
7. Weinreb R, Friedman D, Fechtner R, et al. Risk assessment in the management of patients with ocular hypertension. Am J Ophthalmol 2004; 138: 458-67.
8. Le A, Mukesh BN, McCarty CA, Taylor HR. Risk factors associated with the incidence of open-angle glaucoma: the visual impairment project. Invest Ophthalmol Vis Sci 2003; 44: 3783-9.
9. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998; 126: 487-97.
10. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998; 126: 498-505.
11. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 714-20.
12. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol 2003; 121: 48-56.
13. Bengtsson B, Leske MC, Hyman L, Heijl A, Early Manifest Glaucoma Trial Group. Fluctuation of intraocular pressure and glaucoma progression in the Early Manifest Glaucoma Trial. Ophthalmology 2007; 114: 205-9.
14. Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 2004; 111: 1627-35.
15. Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000; 9: 134-42.
16. EGS Terminology and Guidelines for Glaucoma, 3rd ed. Savona: Dogma; 2008: 11-3.
17. Collaborative Normal-tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998; 126: 498-505.
18. AGIS investigators. The AGIS study: 7: the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130: 429-40.
19. Parc CE, Johnson DH. Long-term outcome of glaucoma filtration surgery. Am J Ophthalmol 2001; 132: 27-35.
20. Kass MA. Compliance and prognosis in glaucoma [editorial]. Arch Ophthalmol 1985; 103: 504.
21. Rossi GCM, Pasinetti GM, Scudeller L, Tinelli C, Milano G, Bianchi PE. Monitoring adherence rates in glaucoma patients using Travatan Dosing Aid: a six months study comparing patients on Travoprost 0.004% and patients on travoprost 0.004%/timolol 0.5% fixed combination. Expert Opin Pharmacother 2010; 11: 499-504.
22. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 1999; 21: 1074-90.
23. Friedman DS, Jampel HD, Congdom NG, Miller R, Quigley HA. The Travatan Dosing Aid accurately records when drops taken. Am J Ophthalmol 2007; 143: 699-701.
24. Flowers B, Wand M, Piltz-Seymour J, et al. Patientsí and physiciansí perception of the Travoprost Dosing Aid: an open-label, Multicenter study of adherence with prostaglandin analogue therapy for open angle glaucoma or ocular hypertension. Clin Ther 2006; 28: 1803-11.
25. Cronin TH, Kahook MY, Lathrop KL, Noeker RJ. Accuracy and performance of a commercially available dosing aid. Br J Ophthalmol 2007; 91: 497-9.
26. Brusini P, Filacorda S. Enhanced Glaucoma Staging System (GSS 2) for classifying functional damage in glaucoma. J Glaucoma 2006; 15: 40-6.
27. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-97.
28. Martínez-Belló C, Chauhan BC, Nicolela MT, McCormick TA, LeBlanc RP. Intraocular pressure and progression of glaucomatous visual field loss. Am J Ophthalmol 2000; 129: 302-8.
29. Tezel G, Siegmund KD, Trinkaus K, Wax MB, Kass MA, Kolker AE. Clinical factors associated with progression of glaucomatous optic disc damage in treated patients. Arch Ophthalmol 2001; 119: 813-8.
30. Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the Early Manifest Glaucoma Trial. Ophthalmology 2007; 114: 1965-72.
31. Okeke CO, Quigley HA, Jampel HD, et al. Interventions improve poor adherence with once daily glaucoma medications in electronically monitored patients Ophthalmology 2009; 116: 2286-93.
32. Okeke CO, Quigley HA, Jampel HD, et al. Adherence with topical glaucoma medication monitored electronically: The Travatan Dosing Aid Study. Ophthalmology 2009; 116: 191-9.